Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Titel:
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Auteur:
Price, Timothy J Peeters, Marc Kim, Tae Won Li, Jin Cascinu, Stefano Ruff, Paul Suresh, Atilli Satya Thomas, Anne Tjulandin, Sergei Zhang, Kathy Murugappan, Swaminathan Sidhu, Roger